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INTRODUCTION
Diamond-Blackfan anemia (DBA) is a chronic congenital
hematological disease characterized by a selective erythroid
regenerative defect (1). The hematological features of DBA
include anemia, reticulocytopenia and bone marrow erythrocy-
topenia, and the main stay of treatment involves corticosteroid
administration and blood transfusion. Although the majority
of patients respond to steroids, some require long-term high-
dose steroid therapy, and some of these patients develop steroid
resistance and require chronic red cell transfusions. 
Red cell enolase deficiency is an enzymopathy, which has
been sparsely reported. To the best of our knowledge, the asso-
ciation between DBA and red cell enolase deficiency has never
been described in the literature. Rather, in DBA, red cell en-
zyme activities including enolase were reported to be above
the normal mean (2). In this report, we describe a case of DBA
with accompanying red cell enolase deficiency in a child, who
after successful bone marrow transplantation (BMT) showed
resolution of anemia as well as normalization of red cell eno-
lase activity.
CASE REPORT
A two-month-old baby girl was diagnosed as having DBA.
Her physical examination was normal except for signs of ane-
mia, and there was no associated skeletal anomaly. At presen-
tation, her hemoglobin was 2.7g/dL, white blood cell count
3,260/mL, platelet count 321,000/mL and reticulocytes 0.42%.
A peripheral blood smear showed macrocytic normochromic
anemia with no evidence of hemolysis. A bone marrow eval-
uation at 10 weeks of age showed a marked decrease in ery-
thropoiesis and maturation arrest of red cell precursors (Fig.
1A). The estimated M:E ratio was 26.8:1. Serology for Par-
vovirus B19 or Epstein-Barr virus revealed no evidence of
active infection (3). After establishing the diagnosis of DBA,
the patient was treated with corticosteroid and showed good
initial response. However, at 3 yr of age, she became steroid
resistant and soon became transfusion dependent. She had
usually been transfused every 4 to 8 weeks and required chelat-
ing treatment on a number of occasions. The anemia got pro-
gressively worsened and reticulocyte counts were low most
of the time. Yet, unexplained reticulocytosis was occasional-
ly seen (Fig. 2).
At 4 yr old, a further evaluation of her chronic anemia inci-
dentally revealed very low enolase activity (0.04 IU/g Hb;
Hb 4.0 g/dL) compared to normal control (normal control
5.19 IU/g Hb; Hb 13 g/dL) while erythrocyte adenosine deam-
inase level (eADA) was within normal range (1.5 IU/g Hb;
normal control 1.6 IU/g Hb) (4). Other red cell enzyme activ-
ities were normal or slightly increased. Her mother and father
626
Jeong A Park
1,2, Yeon Jung Lim
3, 
Hyeon Jin Park
1, Sun Young Kong
4, 
Byung Kiu Park
1, and Thad T. Ghim
1
Pediatric Oncology Center
1, National Cancer Center,
Goyang; Department of Pediatrics
2, Inje University
Haeundae Paik Hospital, Busan; Department of 
Pediatrics
3, Chungnam University Hospital, Daejeon;
Department of Diagnostic Laboratory Medicine
4,
National Cancer Center, Goyang, Korea
Address for Correspondence
Thad T. Ghim, M.D.
Pediatric Oncology Center, National Cancer Center, 
111 Jungbalsan-ro, Ilsandong-gu, Goyang 410-769,
Korea 
Tel : +82.31-920-1653, Fax : +82.31-920-1520
E-mail : thadghim@gmail.com
J Korean Med Sci 2010; 25: 626-9 ISSN 1011-8934
DOI: 10.3346/jkms.2010.25.4.626
Normalization of Red Cell Enolase Level Following Allogeneic Bone
Marrow Transplantation in a Child with Diamond-Blackfan Anemia 
We describe a girl with Diamond-Blackfan anemia with accompanying red cell eno-
lase deficiency. At the age of 9 yr old, the patient received allogeneic bone marrow
transplantation from her HLA-identical sister who had normal red cell enolase activi-
ty. While the post transplant DNA analysis with short tandem repeat has continuous-
ly demonstrated a stable mixed chimerism on follow-up, the patient remains trans-
fusion independent and continues to show a steady increase in red cell enolase
activity for over two and a half years following bone marrow transplantation.
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had normal hemoglobin levels and normal mean corpuscular
volume (MCV), but their enolase activities were subnormal.
On the other hanad, the red cell enolase activity in her younger
sister who subsequently donated marrow was normal (Table 1).
At the age of 7 yr, the patient underwent an allogeneic BMT
from her human leukocyte antigen (HLA) identical sister. The
conditioning regimen was comprised of intravenous busul-
fan 3.2 mg/kg/day over 4 days followed by intravenous cyclo-
phosphamide 60 mg/kg/day for 2 days and rabbit antithy-
mocyte globulin 2.5 mg/kg/day for 3 days. A total of 2.92
×108/kg unmanipulated BM nucleated cells (CD34+ cells:
3.58×106/kg) were infused. Methotrexate and cyclosporine
A were given to prevent graft versus host disease (GVHD).
Granulocyte colony-stimulating factor at 10 g/kg/day was
administrated from day 5 to day 16. Neutrophil engraftment
was achieved on day 15, and platelet engraftment on day 24.
No transplant related morbidity occurred, e.g., infection,
acute GVHD or veno-occlusive disease. Bone marrow aspi-
rates on day 28 showed active trilineage hematopoiesis (Fig.
1B) and mixed chimeric state (recipient DNA: 11.26%) on
Fig. 1. (A) Bone marrow aspirates before BMT showed normocellular marrow with markedly reduced erythropoiesis. (B) Bone marrow aspi-
rates obtained 28 days after BMT showed active trilineage hematopoiesis accompanied with presence of erythropoietic precursors (arrows). 
A B
Fig. 2. This graph displays the changes of the hemoglobin level and reticulocytes counts. While on prednisolone from 2 months to 39 months
of age, the hemoglobin levels increased with transient reticulocytosis, but later gradually decreased. Since 3 yr of age, she had been inter-
mittently transfused, usually every 4 to 8 weeks. She eventually developed transfusion dependency.
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multiplex short tandem repeat analysis (STR) performed
with the AmpFlSTR Blue polymerase chain reaction (PCR)
amplification kit (PE Applied Biosystems, Foster City, CA,
USA) (5). As hoped for, the enolase activity (0.72 IU/g Hb;
normal control 3.4 IU/g Hb) on day 28 after BMT was higher
than that of the low pre-transplant level (Fig. 3). At one year
after BMT, her red cell enolase level had risen further to 6.54
IU/g Hb (normal control 7.76 IU/g Hb), and DNA analy-
sis of the bone marrow aspirates showed a persistent stable
mixed chimerism (recipient DNA 5.08%). She had no longer
required any blood transfusion ever since the time of BMT.
DISCUSSION
Enolase deficiency is extremely rare, and its pathogenesis,
inheritance and clinical manifestation have not been firmly
established. Enolase deficiency is known to be associated with
chromosome 1p locus mutations (1 pter-p36.13) and to cause
chronic nonspecific hemolytic anemia (6). Lachant et al. (7)
described four generations of a Caucasian family with heredi-
tary red cell enolase deficiency. They reported that this dis-
ease entity had a variety of clinical expression with autosomal
dominant inheritance pattern. However, in our case, it doesn’t
seem to correspond to the reported inheritance pattern. 
DBA is also markedly heterogeneous with respect to patho-
genesis, inheritance, and clinical manifestation. DBA is inher-
ited in about 10-20% of cases, and genetic studies have iden-
tified mutations in RPS19 (a ribosomal protein gene) in a
quarter of cases (8). Recent studies have also suggested some
other associated genes, i.e., chromosomes 8p, 10q (RPS24),
1q31 and 15 (RPS17) (9-11). However, in other cases, genetic
linkage with DBA has yet to be identified. This fact suggests
its genetic heterogeneity. Unfortunately, genetic screening
for the patient and her family was not performed at the time
of diagnosis although it could have shed some light in the
understanding of the relationship between enolase deficien-
cy and DBA. 
Unlike the elevated erythrocyte enzyme activities report-
ed both in hypoplasitic anemia and stress-induced environ-
ment of erythropoiesis (2), our patient had a very low eno-
lase level, suggesting that DBA and enolase deficiency might
also coexist. On the other hand, our patient may represent a
hitherto undescribed disease entity expressing both defective
erythropoiesis and enolase deficiency simultaneously. 
Unlike our patient described here, the eADA level is known
to be generally high in DBA patients. However, the role of
eADA in the pathogenesis of DBA has not been established
(12).
There’s a report of successful BMT in a child with a red cell
pyruvate kinase (PK) deficiency (13). After transplant, the
patient achieved a complete donor chimerism, normal hemo-
globin level and normal red cell PK activity. On the other
hand, our patient showed stable mixed chimerism. In non-
malignant hematological disorders, it is believed that com-
plete replacement of the recipient’s hematopoietic system is
not necessarily required to improve the underlying disease
state (14). Despite the danger of graft rejection in mixed chi-
merism, it is known that even a small degree of mixed chime-
rism may improve the disease status in some hematologic
diseases (15, 16). To date, there are too few case reports of
HSCT therapy results in RBC enzymopathies. However, as
demonstrated in our case, mixed chimerism at an 89-95%
level may produce an acceptable outcome in the RBC eno-
lase deficiency. 
In summary, the case presented here uniquely illustrates
that both red cell aplasia and red cell enzymopathy might
coexist, and that successful marrow engrafment even with
the mixed chimerism might correct both defective erythro-
poiesis and the RBC enolase deficiency simultaneously. 
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Enolase 
(IU/g Hb)
Control
(IU/g Hb)
Hb
(g/dL)
MCV 
(fL)
MCH 
(pg)
Reticulo-
cytes (%)
Patient 0.04 5.19 2.7 103.1 32.4 0.42
(pre BMT)
Father 0.09 3.22 17.8 91.5 32.3 0.95
Mother 0.32 3.22 12.9 32.5 34.4 0.65
Sister 6.4 4.2 12.6 80.8 28.1 1.56
Table 1. Red cell enolase levels of the patient, her family mem-
bers, and of normal controls. This table also shows the CBC
results of the family members
Fig. 3. This graph displays the observed erythrocyte enolase level
increase that occurred after BMT.
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